№ files_lp_3_process_7_032052
File format: docx Character count: 14453 File size: 5799 KB
Supplementary material to the study of bacterial RNA polymerase pausing regulation by riboswitches and their ligands, including detailed figures and experimental data related to cryo-EM analysis and molecular dynamics simulations.
Year: 2021
Region / City: Ann Arbor, MI, USA
Subject: Structural Biology, RNA Biomedicine
Document Type: Research Paper
Organization: University of Michigan, Life Sciences Institute, Single Molecule Analysis Group, Biophysics Program
Authors: Adrien Chauvier, Jason C. Porta, Indrajit Deb, Emily Ellinger, Aaron T. Frank, Melanie D. Ohi, Nils G. Walter
Target Audience: Researchers in the field of biochemistry and molecular biology
Period of Validity: N/A
Approval Date: N/A
Modification Date: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Amendment to MBS item 72814 for programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) testing to include testing for advanced triple negative breast cancer (TNBC) patients
Year: 2023
Region / City: Australia
Subject: Health / Oncology
Document Type: Official Announcement
Organization: Department of Health and Aged Care
Author: Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience: Healthcare providers, specialists
Effective Date: 1 September 2023
Approval Date: 10 August 2023
Changes Date: 1 September 2023
Clinical Category: Pathology Services
Procedure Type: Type C
Private Health Insurance Classification: Support List (pathology)
MBS Item: 72814
PBS Listing: pembrolizumab (Keytruda®)
Eligibility Criteria: Advanced TNBC, PD-L1 Combined Positive Score (CPS) ≥10
Consulted Stakeholders: Clinical experts, providers, consumer health representatives
Review and Monitoring: Compliance audits
More Information: www.mbsonline.gov.au
Description: Official update on the inclusion of PD-L1 immunohistochemistry testing for advanced triple negative breast cancer (TNBC) patients under the Medicare Benefits Schedule (MBS) effective 1 September 2023, aligned with PBS listing for pembrolizumab.
Synthesis and characterization of a novel metal complex Cobalt (III) with a tetradentate N,N,O,O-donor ligand and 2,2'-{propane-1,2-diyl- bis[nitrilo(E)methylidene]}bis(6-methoxyphenol)
Year: 2026
Region / city: Not specified
Theme: Coordination Chemistry
Document Type: Research Paper
Institution: Not specified
Author: Not specified
Target audience: Scientists, Chemists
Period of validity: Not specified
Approval date: Not specified
Date of modifications: Not specified
Topics: Pausing Riboswitch Ligand